Skip to main content
editor.ajphr@gmail.com
9409046853
e-ISSN: 2321-3647
American Journal of Pharmacy and Health Research

American Journal of Pharmacy and Health Research

📢 Latest Update: Call for Papers 2026 | Submit Your Research to an International Peer-Reviewed Open Access Pharmacy Journal

📢 Latest Update: Call for Papers 2026 | Submit Your Research to an International Peer-Reviewed Open Access Pharmacy Journal

Current Issue
Volume 14, Issue 11 - 2026 (November 2026 Issue 11)

Volume 14 Issue 11 Cover

Issue Details:

Volume 14 Issue 11 (November 2026 Issue 11)
Total articles: 6
Published: Nov 2, 2026

Issue Description:

Welcome to the 2026 issue of American Journal of Pharmacy and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr H J Patel
Editor-in-Chief
American Journal of Pharmacy and Health Research

Articles in This Issue

Showing 6 of 6 articles
Research PaperID: AJPHR11140000Pages 74-97Open AccessOpen Access

Azoxymethane in Experimental Pharmacology: Molecular Mechanisms, Colorectal Carcinogenesis and Therapeutic Research Applications

Devansh Mehta
Nov 16, 2026

Azoxymethane (AOM) is a synthetic alkylating procarcinogen widely employed in experimental pharmacology, toxicology and molecular oncology for investigating colorectal carcinogenesis. Although it does not possess an established therapeutic indication, its pharmacological and toxicological properties provide an important experimental framework for understanding chemical carcinogenesis and evaluating potential chemopreventive and anticancer interventions. Following metabolic activation, principally through cytochrome P450-dependent pathways, AOM generates methylating intermediates capable of producing DNA adducts, including O⁶-methylguanine. These alterations contribute to mutagenesis, epithelial dysregulation and colorectal tumour initiation. The combination of AOM with dextran sodium sulphate (DSS) has further established a reproducible experimental model of inflammation-associated colorectal cancer. This review examines the historical development, chemical characteristics, pharmacokinetic considerations, metabolic bioactivation, molecular mechanisms, cellular responses and toxicological profile of AOM. Particular attention is given to DNA damage, DNA repair mechanisms, KRAS and Wnt/β-catenin signalling, NF-κB activation, oxidative stress, NLRP3 inflammasome activity, apoptosis, autophagy and interactions with the intestinal microbiome. Contemporary applications in pharmacological research, including chemoprevention, natural-product evaluation, immunotherapy, microbiome-directed interventions and experimental drug screening, are discussed. Recent developments through 2026 highlight the importance of standardising AOM/DSS models and integrating microbiome, metabolomic and lipidomic investigations. The review concludes that AOM remains an important experimental carcinogenesis tool, provided its carcinogenic nature, model limitations and lack of direct therapeutic utility are recognised. Its principal translational value lies in facilitating the discovery and preclinical evaluation of safer and more effective colorectal cancer prevention and treatment strategies.

Azoxymethanechemical carcinogenesismethylazoxymethanolO⁶-methylguaninecolorectal neoplasiaCYP2E1 bioactivation.
116,081 views
34,998 downloads

Contributors:

 Devansh Mehta
Research PaperID: AJPHR11140001Pages 1-12Open AccessOpen Access

In Silico Evaluation of Gossypium Hirsutum Phytoconstituents against Gastric H+/K+-ATPASE

Dr. V.P.Rode, Mr. Aayush Pandit, Hoshal Hirwani, Dr. Nitu Madan, Jagruti Walde, Dr. Amit Maliye
Nov 2, 2026

Methods: Seventeen phytoconstituents of G. hirsutum were selected for molecular docking against the gastric H+/K+-ATPase structure obtained from the Protein Data Bank (PDB ID: 5YLU). Ligands and protein were prepared using appropriate molecular modelling tools, and docking was performed using AutoDock Vina through PyRx. Protein-ligand interactions were subsequently examined using BIOVIA Discovery Studio Visualizer. Physicochemical and drug-likeness characteristics were evaluated using SwissADME. Results: The docking study will identify phytoconstituents exhibiting favorable predicted binding affinities toward gastric H+/K+-ATPase. The compounds showing the most favorable docking scores and relevant interactions with the receptor will be considered priority candidates for further investigation. Drug-likeness analysis will provide additional information regarding their physicochemical properties and compliance with commonly used medicinal-chemistry filters. Conclusion: The proposed computational investigation provides a preliminary structure-based assessment of G. hirsutum phytoconstituents against gastric H+/K+-ATPase. Compounds demonstrating favorable docking profiles may serve as candidates for subsequent experimental evaluation. However, molecular docking predictions alone cannot establish antiulcer efficacy, pharmacological activity, bioavailability, or safety and therefore require validation through appropriate in vitro and in vivo studies.

gastric proton pumpmolecular dockingphytoconstituentsGossypium hirsutumAutoDock Vinadrug-likeness
115,617 views
34,840 downloads

Contributors:

 Dr. V.P.Rode
,
 Mr. Aayush Pandit
,
 Hoshal Hirwani
,
 Dr. Nitu Madan
,
 Jagruti Walde
,
 Dr. Amit Maliye
Research PaperID: AJPHR11140002Pages 13-24Open AccessOpen Access

ASSESSMENT OF INTRAVENOUS HIGH-RISK MEDICATION MANAGEMENT IN A TERTIARY CARE HOSPITAL

Rajat Garg, Hemant Bhardwaj, Anjum Qadir Lone, Dr Tarun Singh, Bimal K Agrawal
Nov 3, 2026

Iatrogenic harm induced from medication occur at a rate more than one fourth in general wards and more than three fourth in ICUs, it estimated that during a critical care stay 1.7 medication errors per patient could be potentially life-threatening especially from drug given intravenously. We Aimed to assess the intravenous high-risk medication management in tertiary care hospital, and analyze utilization of IV high-risk medication dilution, diluent and duration. Methods Prospective controlled study involving 250 participants evaluated the utilization patterns of intravenous high-risk medications in equal divided groups, with a focus on dilution practices, diluent selection, and duration of administration in a critical care unit over a period of six months. A researcher observed this study by reviewing all the Patient Infusion Charts, Critical Care Flow Sheet and Syringe pump/infusions. Baseline severity was assessed using APACHE II and qSOFA scores. Categorical variables were analyzed using the Chi-square test. Results A total of 250 participants were enrolled and equally allocated into two groups 125 intervention and 125 Control. Analyzing the baseline clinical severities parameters including APACHE II scores (p = 0.845) and qSofa (p = 0.589) were distinguished between groups. No statistically significant differences were observed in primary clinical outcomes such as mortality (p =0.447) or discharge status (p = 0.609). A researcher independent double-checking before medication administration was documented in 81 (64.8%) intervention patients compared to 79 (63.2%) control patients (p =0.895). Conclusion In conclusion, primary outcomes were statistically distinct between the study groups, pharmacist-led observation and independent double-checking protocols established structured standardization in IV drug dilution, diluent selection, and infusion rate monitoring. Further research using more sensitive methods to assess key variables will provide a clearer and more comprehensive understanding of the true impact of pharmacist-led care on clinical outcomes. Keywords: High-Risk Medications; Intensive Care Units; Infusions; Patient Safety

High-Risk MedicationsIntensive Care UnitsInfusionsPatient Safety
116,102 views
34,722 downloads

Contributors:

 Rajat Garg
,
 Hemant Bhardwaj
,
 Anjum Qadir Lone
,
 Dr Tarun Singh
,
 Bimal K Agrawal
Review PapersID: AJPHR11140003Pages 25-42Open AccessOpen Access

Helicobacter Pylori–Associated Peptic Ulcer Disease: Epidemiology, Antimicrobial Resistance, and Future Public-Health Strategies

TAPAN KUMAR MAHATO
Nov 13, 2026

Helicobacter pylori remains a significant public health concern because of its association with chronic gastric infection, recurrent peptic ulcer disease (PUD), and increasing antimicrobial resistance (AMR). The review also considers socioeconomic inequalities, diagnostic limitations, and challenges in implementing effective eradication programmes. This narrative review synthesizes current evidence on the global and Indian epidemiology of H. pylori-associated PUD, antimicrobial resistance trends, treatment failures, and their implications for public health and healthcare services. Substantial geographical variation in resistance to metronidazole, clarithromycin, levofloxacin, and amoxicillin, particularly in India, has reduced the effectiveness of several empirical eradication regimens. Effective management requires antimicrobial stewardship, susceptibility-guided therapy, post-treatment confirmation of eradication, and equitable access to reliable diagnostic services. Emerging strategies include molecular resistance testing, vonoprazan-based therapies, adjunctive probiotics, evidence-based investigation of plant-derived antimicrobial compounds, urease inhibitors, and vaccine development. Coordinated clinical, diagnostic, public health, and research efforts are essential to reduce treatment failures, unnecessary antibiotic exposure, and the overall burden of H. pylori infection and associated PUD. Keywords: Helicobacter pylori; Peptic ulcer disease; Antimicrobial resistance; Epidemiology; Antimicrobial stewardship

Helicobacter pyloriPeptic ulcer diseaseAntimicrobial resistanceEpidemiologyAntimicrobial stewardship
115,977 views
34,781 downloads

Contributors:

 TAPAN KUMAR MAHATO
Research PaperID: AJPHR11140004Pages 43-73Open AccessOpen Access

Molecular Mechanisms In the Pathogenesis of Diabetic Nephropathy: Historical Development, Intracellular Signalling Pathways, Molecular Targets and Contemporary Therapeutic Strategies

Devansh Mehta
Nov 16, 2026

Diabetic nephropathy (DN), increasingly described within the broader clinical framework of diabetic kidney disease (DKD), represents a major microvascular complication of diabetes mellitus and a leading contributor to chronic kidney disease and end-stage kidney failure worldwide. Its pathogenesis involves complex interactions among chronic hyperglycaemia, haemodynamic abnormalities, oxidative stress, inflammatory mediators, mitochondrial dysfunction, endothelial injury, podocyte damage and progressive extracellular matrix accumulation. Historically, the understanding of DN has evolved from morphological descriptions of glomerulosclerosis to the identification of hyperfiltration, renin–angiotensin–aldosterone system activation and multiple intracellular signalling networks. This review examines the historical development and molecular basis of DN, emphasising advanced glycation end-products and receptor for advanced glycation end-products signalling, protein kinase C activation, polyol and hexosamine pathways, transforming growth factor-β/Smad signalling, nuclear factor-κB, mitogen-activated protein kinases, phosphatidylinositol-3-kinase/Akt/mTOR, AMP-activated protein kinase, Nrf2/Keap1, Wnt/β-catenin and NLRP3 inflammasome activation. Particular attention is given to podocyte dysfunction, glomerular endothelial abnormalities, tubular metabolic stress, epigenetic regulation and renal fibrosis. Contemporary therapeutic strategies, including renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists, are evaluated alongside landmark clinical trials and emerging molecular interventions. The review also discusses integrated treatment approaches, biomarker-based risk stratification and future therapeutic directions. Understanding the convergence of metabolic, haemodynamic and inflammatory pathways is essential for developing individualised, evidence-based interventions capable of delaying renal disease progression and improving long-term cardiorenal outcomes.

Diabetic kidney diseasediabetic nephropathyAGE–RAGE signallingglomerular hyperfiltrationpodocytopathymitochondrial oxidative stress
116,018 views
34,850 downloads

Contributors:

 Devansh Mehta
Review PapersID: AJPHR11140006Pages 98-116Open AccessOpen Access

Pomegranate Peel Extract-Loaded Hydrogels for Wound Healing: Bioactive Constituents, Mechanisms, Formulation Strategies and Recent Advances Dr. Satish Kilaje¹, Asmita Bhagate¹, Bushra Dafedar¹, Shubham Patil1

Dr. Satish Kilaje, Asmita Bhagate, Bushra Dafedar, Shubham Patil
Nov 16, 2026

Wound healing is a coordinated biological process involving hemostasis, inflammation, proliferation, angiogenesis, re-epithelialization, extracellular-matrix deposition and tissue remodeling. Delayed healing may be associated with oxidative stress, persistent inflammation, microbial infection, impaired angiogenesis and inadequate tissue regeneration. Pomegranate (Punica granatum L.) peel is a rich source of polyphenolic constituents, particularly hydrolyzable tannins and phenolic acids, including punicalagin, punicalin, ellagic acid and gallic acid. These constituents have demonstrated antioxidant, anti-inflammatory and antimicrobial activities in experimental studies. However, direct topical application of plant extracts may be limited by instability, short residence time and uncontrolled release. Hydrogel wound dressings provide hydrated polymeric networks that can maintain a moist wound environment, absorb exudate and support localized delivery of bioactive compounds. Experimental investigations have examined pomegranate peel extract (PPE) in gelatin membranes, hyaluronic-acid/silver-nanoparticle systems, pH-responsive starch-based films, chitosan/PEG/ZnO nanocomposites, carbomer gels and gelatin methacryloyl (GelMA) hydrogels containing pomegranate-peel-derived extracellular vesicles. These studies report encouraging preclinical findings, including improvements in wound closure, epithelialization, granulation tissue formation, collagen deposition and infection-associated outcomes. This review focuses on the phytochemical composition of pomegranate peel, biological mechanisms relevant to wound repair, hydrogel and related polymeric dressing strategies, formulation and characterization considerations, recent technological developments, limitations and future perspectives. The available evidence supports further investigation of PPE-based delivery systems; however, extract standardization, mechanistic validation, long-term safety assessment, manufacturing reproducibility and clinical evaluation remain necessary before clinical translation. Despite this growing body of work, a focused comparison of PPE-loaded hydrogel and related polymeric wound-dressing systems is needed. The reported formulations differ in extract preparation, phytochemical composition, polymer selection, crosslinking strategy, release characteristics and biological evaluation. These differences complicate comparisons of formulation performance and therapeutic outcomes. Accordingly, this review integrates pomegranate peel phytochemistry with hydrogel formulation science and wound-healing biology, with emphasis on formulation strategies, characterization, preclinical evidence, technological advances and barriers to clinical translation. Pomegranate peel contains hydrolyzable tannins, phenolic acids, flavonoids and other secondary metabolites. The relative abundance of these constituents varies with cultivar, geographical origin, fruit maturity, dying

Punica granatumpomegranate peelpomegranate peel extracthydrogelwound healingwound dressing
116,129 views
35,011 downloads

Contributors:

 Dr. Satish Kilaje
,
 Asmita Bhagate
,
 Bushra Dafedar
,
 Shubham Patil
Whatsapp